China (Mainland)
Premiumsupplier
Wholesaler Best price 171335-80-1Fast Delivery Exatecan CAS NO.171335-80-1
- Min.Order: 10 Metric Ton
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- 171335-80-1Wholesaler
- Best price 171335-80-1
- Fast Delivery Exatecan
Quick Details
- ProName: Wholesaler Best price 171335-80-1Fast ...
- CasNo: 171335-80-1
- Molecular Formula: C24H22FN3O4
- Appearance: Powder or liquid
- Application: Medicinal Chemistry Biomedicine Phar...
- DeliveryTime: Goods in stock
- PackAge: According to customer
- Port: Shanghai
- ProductionCapacity: Metric Ton/Day
- Purity: 97%
- Storage: Store in a tightly closed container, i...
- Transportation: Fedex,DHL,TNT,BY SEA and BY AIR
- LimitNum: 10 Metric Ton
- Moisture Content: 5%
- Grade: Industrial Grade，Reagent Grade
Superiority
Details
Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death.
Exatecan is a potent topoisomerase I inhibitor, with an IC50 of 0.975 μg/mL. Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI50s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively. Exatecan Mesylate (DX-8951f) displays cytotoxic activities against PC-6, PC-6/SN2-5 cells, with mean GI50s of 0.186 and 0.395 ng/mL, respctively. Exatecan Mesylate (34 nM) stabilizes DNA-TopoI complexes in PC-6 and PC-6/SN2-5 cells.
Exatecan Mesylate (DX-8951f, 3.325-50 mg/kg, i.v.) exhibits antitumor activities in the mice model bearing tumor cells, without toxic death[1]. Exatecan Mesylate (15, 25 mg/kg, i.v.) hightly inhibits MIA-PaCa, BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3. Exatecan Mesylate (15, 25 mg/kg, i.v.) also significantly suppresses BxPC-3 lymphatic metastasis and completely eliminates lung metastasis in the BxPC-3 late-stage cancer model.